Expanding access to SARS-CoV-2 IgG and IgM serologic testing using fingerstick whole blood, plasma, and rapid lateral flow assays

Anderson, Mark; Holzmayer, Vera; Vallari, Ana; Taylor, Russell; Moy, James; Cloherty, Gavin

Serologic testing for SARS-CoV-2 antibodies can be used to confirm diagnosis, estimate seroprevalence, screen convalescent plasma donors, and assess vaccine efficacy. Dried blood spot (DBS) samples have been used for serology testing of various diseases in resource-limited settings. We examined the use of DBS samples and capillary blood (fingerstick) plasma collected in Microtainer tubes for SARS-CoV-2 testing with the automated Abbott ARCHITECTâ„¢ SARS-CoV-2 IgG and IgM assays and use of venous whole blood with a prototype PANBIOâ„¢ rapid point-of-care lateral flow SARS-CoV-2 IgG assay. The ARCHITECTâ„¢ SARS-CoV-2 IgG assay was initially optimized for use with DBS, venous and capillary plasma, and venous whole blood collected from patients with symptoms and PCR-confirmed COVID-19 and negative asymptomatic controls. Linearity and reproducibility was confirmed with 3 contrived DBS samples, along with sample stability and signal recovery after 14 days. ARCHITECTâ„¢ SARS-CoV-2 IgG and IgM assay results showed high concordance between fingerstick DBS and venous DBS samples, and between fingerstick DBS and venous whole blood samples (n=61). Fingerstick plasma collected in Microtainer tubes (n=109) showed 100% concordant results (R(2)=0.997) with matched patient venous plasma on the ARCHITECTâ„¢ SARS-CoV-2 IgG assay. High concordance of assay results (92.9% positive, 100% negative) was also observed for the PANBIOâ„¢ SARS-CoV-2 IgG assay compared to the ARCHITECTâ„¢ SARS-CoV-2 IgG assay run with matched venous plasma (n=61). Fingerstick DBS and plasma samples are easy and inexpensive to collect and, along with the use of rapid point-of-care testing platforms, will expand access to SARS-CoV-2 serology testing, particularly in resource-limited areas.